{"id":1328,"date":"2024-07-29T13:55:58","date_gmt":"2024-07-29T05:55:58","guid":{"rendered":"https:\/\/flcube.com\/?p=1328"},"modified":"2024-10-14T22:56:51","modified_gmt":"2024-10-14T14:56:51","slug":"yipinhong-pharmacy-repays-36-7-million-in-bromhexine-marketing-settlement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1328","title":{"rendered":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement"},"content":{"rendered":"\n

Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by ‘colluding with other manufacturers on drug filings and quotations,’ which constituted unfair competition and harmed the legitimate interests of purchasers and other filing manufacturers. These actions occurred during the seventh round of the national volume-based procurement (VBP) program for the drug. Bromhexine, a cough treatment originally developed by French pharmaceutical giant Sanofi, was at the center of the case.<\/p>\n\n\n\n

The repayment amount is based on Yipinhong Pharmacy’s sales of bromhexine from 2022 to the present, with the full financial impact on the company’s annual status still to be determined.<\/p>\n\n\n\n

Bromhexine was included in the 7th VBP round in July 2022, where four domestic manufacturers, including SSY Group, Yipinhong, Renhe Yikang, and Medcalo, secured tender spots with contracts valued at RMB 240 million, RMB 130 million, RMB 120 million, and RMB 140 million, respectively. The companies won their bids with unusually high offers just 20% below the ceiling price for bromhexine. The procurement cycle for VBP drugs typically spans three years.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[1126,82,370],"class_list":["post-1328","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-she-300723","tag-vbp-voluem-based-procurement","tag-yipinhong-pharmacy"],"yoast_head":"\nYipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by 'colluding with other manufacturers on drug filings and quotations,' which constituted unfair competition and harmed the legitimate interests of purchasers and other filing manufacturers. These actions occurred during the seventh round of the national volume-based procurement (VBP) program for the drug. Bromhexine, a cough treatment originally developed by French pharmaceutical giant Sanofi, was at the center of the case.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1328\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1328\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:55:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T14:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement\",\"datePublished\":\"2024-07-29T05:55:58+00:00\",\"dateModified\":\"2024-10-14T14:56:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 300723\",\"VBP (voluem-based procurement)\",\"Yipinhong Pharmacy\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1328#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1328\",\"name\":\"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-29T05:55:58+00:00\",\"dateModified\":\"2024-10-14T14:56:51+00:00\",\"description\":\"Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by 'colluding with other manufacturers on drug filings and quotations,' which constituted unfair competition and harmed the legitimate interests of purchasers and other filing manufacturers. These actions occurred during the seventh round of the national volume-based procurement (VBP) program for the drug. Bromhexine, a cough treatment originally developed by French pharmaceutical giant Sanofi, was at the center of the case.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1328\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1328#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement - Insight, China's Pharmaceutical Industry","description":"Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by 'colluding with other manufacturers on drug filings and quotations,' which constituted unfair competition and harmed the legitimate interests of purchasers and other filing manufacturers. These actions occurred during the seventh round of the national volume-based procurement (VBP) program for the drug. Bromhexine, a cough treatment originally developed by French pharmaceutical giant Sanofi, was at the center of the case.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1328","og_locale":"en_US","og_type":"article","og_title":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1328","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-29T05:55:58+00:00","article_modified_time":"2024-10-14T14:56:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1328#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1328"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement","datePublished":"2024-07-29T05:55:58+00:00","dateModified":"2024-10-14T14:56:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1328"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 300723","VBP (voluem-based procurement)","Yipinhong Pharmacy"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1328#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1328","url":"https:\/\/flcube.com\/?p=1328","name":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-29T05:55:58+00:00","dateModified":"2024-10-14T14:56:51+00:00","description":"Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by 'colluding with other manufacturers on drug filings and quotations,' which constituted unfair competition and harmed the legitimate interests of purchasers and other filing manufacturers. These actions occurred during the seventh round of the national volume-based procurement (VBP) program for the drug. Bromhexine, a cough treatment originally developed by French pharmaceutical giant Sanofi, was at the center of the case.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1328#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1328"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1328#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1328"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1328\/revisions"}],"predecessor-version":[{"id":6525,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1328\/revisions\/6525"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}